デフォルト表紙
市場調査レポート
商品コード
1485082

放射性医薬品市場- 世界の産業規模、シェア、動向、機会、予測、タイプ別、供給源別、エンドユーザー別、地域別、競合別、2019-2029年

Radiopharmaceuticals Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Source, By End user, By Region and Competition, 2019-2029F

出版日: | 発行: TechSci Research | ページ情報: 英文 180 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.74円

こちらのレポートには、数時間(ご購入金額の10%)分のアナリストへの質問/追加調査サービスが含まれております。

放射性医薬品市場- 世界の産業規模、シェア、動向、機会、予測、タイプ別、供給源別、エンドユーザー別、地域別、競合別、2019-2029年
出版日: 2024年05月24日
発行: TechSci Research
ページ情報: 英文 180 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次
概要

放射性医薬品の世界市場規模は2023年に55億2,000万米ドルとなり、予測期間では2029年までCAGR 5.25%で着実な成長が予測されています。

放射性医薬品は核医学分野で極めて重要なコンポーネントとして登場し、診断と治療において重要な役割を果たしています。これらの特殊な医薬品は放射線を放出する放射性同位元素を含んでおり、ヘルスケア専門家が様々な病状を可視化し治療することを可能にしています。世界の放射性医薬品市場は、技術の進歩、慢性疾患の有病率の増加、個別化医療に対する需要の高まりなどを背景に、近年大きな成長を遂げています。世界の放射性医薬品市場は、疾患の早期診断と的確な治療が重視されるようになり、力強い成長を遂げています。市場は主に診断用放射性医薬品と治療用放射性医薬品に区分され、それぞれが全体の拡大に寄与しています。診断用放射性医薬品は、陽電子放射断層撮影法(PET)や単光子放射コンピュータ断層撮影法(SPECT)などの画像診断に広く使用され、臓器や組織の機能に関する貴重な洞察を提供しています。

市場概要
予測期間 2025-2029
市場規模:2023年 55億2,000万米ドル
市場規模:2029年 74億3,000万米ドル
CAGR:2024年~2029年 5.25%
急成長セグメント 診断 放射性医薬品
最大市場 北米

市場促進要因

慢性疾患の増加が放射性医薬品世界市場を牽引

政府のイニシアチブと資金調達が放射性医薬品の世界市場を牽引

主な市場課題

高い生産コスト

サプライチェーンの制約

主な市場動向

技術の進歩

画像診断手順の増加

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の放射性医薬品市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • タイプ別(診断用放射性医薬品、治療用放射性医薬品)
    • 供給源別(原子炉とサイクロトロン)
    • エンドユーザー別(病院・診療所、診断画像センター、その他)
    • 企業別(2023)
    • 地域別
  • 市場マップ

第6章 北米の放射性医薬品市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • タイプ別
    • 供給源別
    • エンドユーザー別
    • 国別
  • 北米:国別分析
    • 米国
    • メキシコ
    • カナダ

第7章 欧州の放射性医薬品市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • タイプ別
    • 供給源別
    • エンドユーザー別
    • 国別
  • 欧州:国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第8章 アジア太平洋地域の放射性医薬品市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • タイプ別
    • 供給源別
    • エンドユーザー別
    • 国別
  • アジア太平洋地域:国別分析
    • 中国
    • インド
    • 韓国
    • 日本
    • オーストラリア

第9章 南米の放射性医薬品市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • タイプ別
    • 供給源別
    • エンドユーザー別
    • 国別
  • 南米:国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの放射性医薬品市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • タイプ別
    • 供給源別
    • エンドユーザー別
    • 国別
  • 中東・アフリカ:国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 合併および買収(該当する場合)
  • 製品の発売(ある場合)
  • 最近の動向

第13章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第14章 競合情勢

  • PharmaLogic Holdings LLC
  • Jubilant Radiopharma
  • China Isotope & Radiation Corporation
  • Siemens Healthineers AG
  • SHINE Technologies, LLC
  • Ion Beam Applications SA
  • Global Medical Solutions
  • BWX Technologies. Inc
  • Coqui Radio Pharmaceuticals Corp.
  • Evergreen Theragnostics, Inc.

第15章 戦略的提言

第16章 調査会社について・免責事項

目次
Product Code: 23964

Global Radiopharmaceuticals Market was valued at USD 5.52 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 5.25% through 2029. Radiopharmaceuticals have emerged as a pivotal component in the field of nuclear medicine, playing a crucial role in diagnostics and therapy. These specialized pharmaceuticals contain radioactive isotopes that emit radiation, enabling healthcare professionals to visualize and treat various medical conditions. The global radiopharmaceuticals market has witnessed significant growth in recent years, driven by technological advancements, increasing prevalence of chronic diseases, and a rising demand for personalized medicine. The global radiopharmaceuticals market has experienced robust growth, with an increasing emphasis on early disease diagnosis and precise treatment. The market is primarily segmented into diagnostic and therapeutic radiopharmaceuticals, each contributing to the overall expansion. Diagnostic radiopharmaceuticals are widely used in imaging procedures like positron emission tomography (PET) and single-photon emission computed tomography (SPECT), providing valuable insights into the functioning of organs and tissues.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 5.52 Billion
Market Size 2029USD 7.43 Billion
CAGR 2024-20295.25%
Fastest Growing SegmentDiagnostic Radiopharmaceuticals
Largest MarketNorth America

Key Market Drivers

Rising Incidence of Chronic Diseases is Driving the Global Radiopharmaceuticals Market

In recent years, the global healthcare landscape has witnessed a significant surge in the incidence of chronic diseases, posing a formidable challenge to healthcare providers and policymakers worldwide. Chronic diseases, such as cancer, cardiovascular diseases, and neurological disorders, are on the rise, necessitating advanced diagnostic and therapeutic solutions. The growing demand for precision medicine has propelled the global radiopharmaceuticals market, playing a pivotal role in the diagnosis and treatment of various chronic conditions. Cancer continues to be a leading cause of morbidity and mortality worldwide. The increasing prevalence of various types of cancer has led to a growing demand for advanced diagnostic tools to detect the disease at an early stage. Radiopharmaceuticals, particularly those used in PET scans, play a crucial role in accurately diagnosing and staging cancer, enabling healthcare professionals to tailor treatment plans for individual patients. Technological advancements in the field of nuclear medicine have led to the development of novel radiopharmaceuticals with enhanced diagnostic and therapeutic capabilities. The integration of artificial intelligence and molecular imaging techniques has further improved the precision and efficiency of radiopharmaceutical applications, driving market growth.

The global population is aging rapidly, leading to an increased prevalence of chronic cardiovascular diseases. Radiopharmaceuticals are instrumental in diagnosing heart conditions, evaluating myocardial perfusion, and assessing cardiac function. As the aging demographic expands, the demand for cardiovascular imaging using radiopharmaceuticals is expected to grow significantly. Neurological disorders, such as Alzheimer's disease and Parkinson's disease, are becoming more prevalent, particularly among the elderly population. PET imaging using radiopharmaceuticals allows for early detection and monitoring of these disorders, facilitating timely intervention and personalized treatment strategies. Radiopharmaceuticals are not limited to diagnostics; they also play a crucial role in therapeutic applications, especially in oncology.

Government Initiatives and Funding is Driving the Global Radiopharmaceuticals Market

Governments across the globe are recognizing the importance of radiopharmaceuticals in improving healthcare outcomes and are actively supporting the industry through various initiatives and funding programs. These initiatives aim to promote research and development, enhance infrastructure, and ensure accessibility to cutting-edge diagnostic and therapeutic solutions. Governments are allocating substantial funds to support research and development activities in the radiopharmaceuticals sector. These funds are crucial in fostering innovation, encouraging the development of new radiopharmaceuticals, and advancing technologies that enhance diagnostic accuracy and treatment effectiveness.

Governments are investing in the establishment and upgrade of nuclear medicine facilities and infrastructure. This includes the procurement of state-of-the-art imaging equipment and the development of specialized radiopharmaceutical production centers. These initiatives are instrumental in ensuring the availability of high-quality radiopharmaceuticals for diagnostic and therapeutic applications. To address the growing demand for skilled professionals in the field of nuclear medicine, governments are initiating training and education programs. These programs aim to enhance the skills of healthcare professionals involved in the handling and administration of radiopharmaceuticals, ensuring the safe and effective use of these agents.

Key Market Challenges

High Production Costs

The production of radiopharmaceuticals involves the synthesis of radioisotopes, which is a complex and resource-intensive process. The limited number of facilities capable of producing these isotopes increases competition and drives up production costs. Ensuring the quality, safety, and stability of the radiopharmaceuticals adds to the intricacy of the manufacturing process. The stringent regulatory requirements for radiopharmaceutical production contribute significantly to the high costs. Adhering to strict quality control measures and ensuring compliance with various international standards demand substantial investments in equipment, personnel, and facilities. Meeting these regulatory standards is crucial to guarantee the safety of patients and healthcare professionals.

Many radioisotopes used in radiopharmaceuticals have short half-lives, ranging from minutes to hours. This necessitates quick and efficient manufacturing processes to ensure the viability of the product upon reaching medical facilities. The need for specialized infrastructure and equipment to handle these short-lived isotopes further adds to the overall production costs. Continuous innovation and research are vital for the development of new radiopharmaceuticals with enhanced diagnostic and therapeutic capabilities. Funding extensive research programs and clinical trials to demonstrate the efficacy and safety of these new compounds is a resource-intensive endeavor, contributing to the overall high production costs. The relatively small market for radiopharmaceuticals limits the opportunities for achieving economies of scale. The production volumes are often lower compared to traditional pharmaceuticals, leading to higher per-unit production costs. This lack of scale efficiencies makes it challenging for manufacturers to reduce costs and offer competitive pricing.

Supply Chain Constraints

Supply chain constraints represent another significant challenge facing the global radiopharmaceuticals market. Radiopharmaceuticals are highly specialized products that require precise manufacturing processes, stringent quality control measures, and specialized infrastructure for production, distribution, and storage. As a result, the radiopharmaceutical supply chain is inherently complex and susceptible to disruptions.

One of the primary supply chain challenges is the limited availability of radioisotopes used in the production of radiopharmaceuticals. Many radiopharmaceuticals rely on isotopes such as technetium-99m (Tc-99m), which have short half-lives and must be produced using nuclear reactors or cyclotrons. However, the global supply of Tc-99m and other critical radioisotopes is often constrained by factors such as reactor shutdowns, supply chain disruptions, and geopolitical tensions.

The transportation and logistics involved in distributing radiopharmaceuticals present additional challenges. Radiopharmaceuticals have strict temperature and radiation shielding requirements to ensure product stability and safety during transit. Delays or mishandling during transportation can compromise product quality and pose radiation safety risks to personnel and the public.

The limited shelf life of radiopharmaceuticals adds complexity to inventory management and distribution logistics. Manufacturers must carefully manage production schedules, distribution networks, and inventory levels to minimize waste and ensure timely delivery to healthcare facilities.

Key Market Trends

Technological Advancements

In the dynamic landscape of healthcare, technological advancements play a pivotal role in shaping the future of medical diagnostics and treatment. One such domain witnessing remarkable growth is the global radiopharmaceuticals market. Radiopharmaceuticals, compounds containing radioactive isotopes, have become indispensable tools in the fields of nuclear medicine and molecular imaging. The surge in technological innovations is propelling this market to new heights, offering enhanced diagnostic capabilities and more targeted therapeutic options. One of the key drivers behind the growth of the radiopharmaceuticals market is the continuous evolution of imaging modalities. The integration of advanced imaging technologies, such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT), has significantly improved the accuracy and precision of medical diagnostics. These technologies enable healthcare professionals to visualize and assess physiological processes at the molecular level, allowing for earlier and more accurate disease detection.

PET imaging, for instance, has gained prominence due to its ability to provide detailed information about metabolic processes, aiding in the diagnosis and monitoring of various conditions, including cancer, cardiovascular diseases, and neurological disorders. The development of hybrid imaging systems that combine PET with other imaging modalities, such as computed tomography (CT) or magnetic resonance imaging (MRI), further enhances the diagnostic capabilities of radiopharmaceuticals. Beyond diagnostics, technological advancements are also reshaping the landscape of therapeutic radiopharmaceuticals. Precision medicine, guided by molecular imaging and targeted therapies, is becoming a reality. Advances in radionuclide therapy, particularly in the treatment of cancer, are creating opportunities for more effective and personalized interventions. Targeted alpha-particle therapy, for instance, is gaining attention for its ability to deliver highly localized radiation to cancer cells while sparing surrounding healthy tissue. This approach minimizes collateral damage and reduces the side effects associated with traditional radiotherapy. The development of theranostic agents-radiopharmaceuticals that combine both diagnostic and therapeutic properties-enables clinicians to tailor treatment plans based on individual patient characteristics.

Rise in Diagnostic Imaging Procedures

Primary drivers of growth in the global radiopharmaceuticals market include the increasing demand for diagnostic imaging procedures. Radiopharmaceuticals play a crucial role in nuclear medicine imaging techniques such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT), which are used for the diagnosis and staging of various diseases, including cancer, cardiovascular disorders, and neurological conditions.

PET imaging, in particular, has witnessed rapid adoption due to its ability to provide high-resolution, three-dimensional images of metabolic processes within the body. PET radiopharmaceuticals such as fluorodeoxyglucose (FDG) are widely used for oncology imaging, allowing clinicians to detect and monitor tumors, assess treatment response, and plan personalized treatment strategies for cancer patients.

Advancements in hybrid imaging technologies, such as PET/CT and PET/MRI, have further expanded the applications of radiopharmaceuticals in diagnostic imaging. These hybrid imaging modalities combine the functional information provided by PET with the anatomical detail offered by CT or MRI, enabling more accurate localization and characterization of disease processes.

The rise in diagnostic imaging procedures is driven by factors such as the increasing prevalence of chronic diseases, aging population demographics, and growing awareness of the importance of early disease detection and prevention. As a result, the global market for radiopharmaceuticals used in diagnostic imaging is poised for continued growth, with opportunities for innovation and market expansion in emerging applications and regions.

Segmental Insights

Type Insights

Based on the category of type, Diagnostic Radiopharmaceuticals emerged as the dominant segment in the global market for Radiopharmaceuticals in 2023. Diagnostic radiopharmaceuticals are radioisotopes combined with a pharmaceutical agent to create a compound that can be administered to a patient for imaging purposes. These compounds emit gamma rays, which can be detected by imaging devices such as gamma cameras or PET scanners. The ability to visualize the physiological functions of organs and tissues at a molecular level makes diagnostic radiopharmaceuticals an invaluable tool for clinicians. The rising prevalence of chronic diseases, including cancer, cardiovascular disorders, and neurological conditions, has led to an increased demand for accurate diagnostic tools. Diagnostic radiopharmaceuticals provide clinicians with valuable information about the extent and nature of diseases, enabling them to formulate precise treatment plans.

Technological advancements in imaging devices, such as Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET), have significantly contributed to the growth of the diagnostic radiopharmaceuticals market. These technologies offer high-resolution images and improved sensitivity, enhancing the diagnostic capabilities of radiopharmaceuticals.

End User Insights

The Hospitals & Clinics segment is projected to experience rapid growth during the forecast period. Hospitals and clinics are primary healthcare facilities where patients undergo diagnostic imaging procedures. The increasing prevalence of chronic diseases and the growing emphasis on early and accurate diagnosis have led to a surge in the demand for radiopharmaceuticals in these settings. As a result, hospitals and clinics have become major consumers of radiopharmaceuticals, contributing significantly to market growth.

Cancer is a global health concern, and the demand for effective diagnostic and therapeutic solutions is on the rise. Radiopharmaceuticals are extensively used in oncology for cancer imaging, staging, and treatment. The ability of radiopharmaceuticals to target and visualize specific cancer cells makes them invaluable in the diagnosis and monitoring of various types of cancers. Hospitals and clinics are at the forefront of cancer care, offering a comprehensive range of services from screening to treatment. The integration of radiopharmaceuticals into cancer diagnostics and treatment protocols has propelled the demand in these healthcare settings. The increasing incidence of cancer cases worldwide has further boosted the utilization of radiopharmaceuticals in hospitals and clinics, solidifying their dominance in the global market.

Regional Insights

North America emerged as the dominant region in the global Radiopharmaceuticals market in 2023, holding the largest market share in terms of value. North America has been at the forefront of technological innovation in the healthcare sector. The region's commitment to research and development has led to the introduction of cutting-edge radiopharmaceuticals and imaging technologies. This technological leadership enhances diagnostic accuracy and enables more targeted and effective treatments. The robust healthcare infrastructure in North America supports the seamless integration of radiopharmaceuticals into medical practices. Access to state-of-the-art facilities and a well-established network of healthcare providers facilitates the widespread adoption of nuclear medicine procedures, contributing to the region's dominance.

Key Market Players

PharmaLogic Holdings LLC

Jubilant Radiopharma

China Isotope & Radiation Corporation

Siemens Healthineers AG

SHINE Technologies, LLC

Ion Beam Applications SA

Global Medical Solutions

BWX Technologies. Inc

Coqui Radio Pharmaceuticals Corp.

Evergreen Theragnostics, Inc.

Report Scope:

In this report, the Global Radiopharmaceuticals Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Radiopharmaceuticals Market, By Type:

    Diagnostic Radiopharmaceuticals Therapeutic Radiopharmaceuticals

Radiopharmaceuticals Market, By Source:

    Nuclear Reactors Cyclotrons

Radiopharmaceuticals Market, By End User:

    Hospitals & Clinics Diagnostics imaging centre Others

Radiopharmaceuticals Market, By Region:

    North America

United States

Canada

Mexico

    Europe

France

United Kingdom

Italy

Germany

Spain

    Asia-Pacific

China

India

Japan

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Radiopharmaceuticals Market.

Available Customizations:

Global Radiopharmaceuticals market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Radiopharmaceuticals Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Diagnostic Radiopharmaceuticals, Therapeutic Radiopharmaceuticals)
    • 5.2.2. By Source (Nuclear Reactors and Cyclotrons)
    • 5.2.3. By End User (Hospitals & Clinics, Diagnostics imaging centre, Others)
    • 5.2.4. By Company (2023)
    • 5.2.5. By Region
  • 5.3. Market Map

6. North America Radiopharmaceuticals Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Source
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Radiopharmaceuticals Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Source
        • 6.3.1.2.3. By End User
    • 6.3.2. Mexico Radiopharmaceuticals Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Source
        • 6.3.2.2.3. By End User
    • 6.3.3. Canada Radiopharmaceuticals Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Source
        • 6.3.3.2.3. By End User

7. Europe Radiopharmaceuticals Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Source
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Radiopharmaceuticals Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Source
        • 7.3.1.2.3. By End User
    • 7.3.2. Germany Radiopharmaceuticals Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Source
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Radiopharmaceuticals Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Source
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Radiopharmaceuticals Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Source
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Radiopharmaceuticals Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Source
        • 7.3.5.2.3. By End User

8. Asia-Pacific Radiopharmaceuticals Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Source
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Radiopharmaceuticals Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Source
        • 8.3.1.2.3. By End User
    • 8.3.2. India Radiopharmaceuticals Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Source
        • 8.3.2.2.3. By End User
    • 8.3.3. South Korea Radiopharmaceuticals Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Source
        • 8.3.3.2.3. By End User
    • 8.3.4. Japan Radiopharmaceuticals Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Source
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Radiopharmaceuticals Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Source
        • 8.3.5.2.3. By End User

9. South America Radiopharmaceuticals Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Source
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Radiopharmaceuticals Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Source
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Radiopharmaceuticals Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Source
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Radiopharmaceuticals Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Source
        • 9.3.3.2.3. By End User

10. Middle East and Africa Radiopharmaceuticals Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Source
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Radiopharmaceuticals Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Source
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Radiopharmaceuticals Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Source
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Radiopharmaceuticals Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Source
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porters Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. PharmaLogic Holdings LLC
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Jubilant Radiopharma
  • 14.3. China Isotope & Radiation Corporation
  • 14.4. Siemens Healthineers AG
  • 14.5. SHINE Technologies, LLC
  • 14.6. Ion Beam Applications SA
  • 14.7. Global Medical Solutions
  • 14.8. BWX Technologies. Inc
  • 14.9. Coqui Radio Pharmaceuticals Corp.
  • 14.10. Evergreen Theragnostics, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer